Treatment
Venetoclax clinical trials
We’re tracking 282 recruiting studies that include Venetoclax, each written for real people, not researchers, below.
Recruiting studies
- NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06328179Recruiting
VHEA treatment for leukemia with KMT2A gene changes
This trial tests a combination treatment (VHEA) for adults with newly diagnosed or relapsed acute myeloid leukemia (AML) that has a specific genetic change called KMT2A. It aims to see if this treatment is safe and effective for patients who meet certain health requirements.
Huai'an, JiangsuAges 18–60 - NCT06372717RecruitingPhase 1
Testing APL-4098 alone or combined for AML or MDS
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
Clayton, VictoriaAges 18 years+ - NCT06387121RecruitingPhase 2
Low-dose chemo plus immune drugs for new B-ALL
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06390306Recruiting
Combination therapy for advanced CML
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06451861RecruitingPhase 2
Testing a new drug combo for newly diagnosed AML
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
Dongguan, GuangdongAges 18 years+ - NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
TianjinAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06496308RecruitingPhase 3
Adding orelabrutinib to standard therapy for mantle cell lymphoma
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
ShanghaiAges 18–80 - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT06536010Recruiting
Testing a new combination therapy for AML
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Huai'an, JiangsuAges 18–75 - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
Birmingham, AlabamaAges 12 years+ - NCT06634394RecruitingPhase 1
Study of APVO436 for untreated AML patients
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Denver, ColoradoAges 18 years+ - NCT06651229RecruitingPhase 1
Study of JNJ-90189892 for blood cancers
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
ConcordAges 18 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80 - NCT06192979Recruiting
First-line treatment for AL amyloidosis with t(11;14)
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
Beijing, Beijing MunicipalityAges Any age - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06742463RecruitingPhase 2
VHAG for relapsed or refractory T-cell acute leukemia
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hangzhou, ZhejiangAges 14–74 - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT07007949RecruitingPhase 2
New drug combo for adult AML with IDH1 mutation
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
Suzhou, JiangsuAges 18 years+ - NCT07023588RecruitingPhase 2
Optimizing AML treatment based on early response
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Changchun, JilinAges 18 years+ - NCT07044544RecruitingPhase 1
New drug combo in stem cell transplant for myeloid cancers
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Birmingham, AlabamaAges 18–75
Common questions
- Are there clinical trials studying Venetoclax?
- Yes. Clin2 currently lists 282 recruiting studies that include Venetoclax, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Venetoclax trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Venetoclax an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Venetoclax or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.